These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25184245)

  • 41. The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
    Black WC; Percival MD
    Chembiochem; 2006 Oct; 7(10):1525-35. PubMed ID: 16921579
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preparation of active recombinant cathepsin K expressed in bacteria as inclusion body.
    Hwang HS; Chung HS
    Protein Expr Purif; 2002 Aug; 25(3):541-6. PubMed ID: 12182837
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recent developments in cathepsin K inhibitor design.
    Grabowskal U; Chambers TJ; Shiroo M
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):619-30. PubMed ID: 16159024
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity.
    Lecaille F; Choe Y; Brandt W; Li Z; Craik CS; Brömme D
    Biochemistry; 2002 Jul; 41(26):8447-54. PubMed ID: 12081494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Probing cathepsin K activity with a selective substrate spanning its active site.
    Lecaille F; Weidauer E; Juliano MA; Brömme D; Lalmanach G
    Biochem J; 2003 Oct; 375(Pt 2):307-12. PubMed ID: 12837132
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rat cathepsin K: Enzymatic specificity and regulation of its collagenolytic activity.
    Lecaille F; Chazeirat T; Bojarski KK; Renault J; Saidi A; Prasad VGNV; Samsonov S; Lalmanach G
    Biochim Biophys Acta Proteins Proteom; 2020 Feb; 1868(2):140318. PubMed ID: 31740411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Highly Conserved Arg Residue of ERFNIN Motif of Pro-Domain is Important for pH-Induced Zymogen Activation Process in Cysteine Cathepsins K and L.
    Aich P; Biswas S
    Cell Biochem Biophys; 2018 Jun; 76(1-2):219-229. PubMed ID: 29322360
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interplay between tetrameric structure, enzymatic activity and allosteric regulation of human dipeptidyl-peptidase I.
    Rebernik M; Snoj T; Klemenčič M; Novinec M
    Arch Biochem Biophys; 2019 Oct; 675():108121. PubMed ID: 31574257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor necrosis factor alpha stimulates cathepsin K and V activity via juxtacrine monocyte-endothelial cell signaling and JNK activation.
    Keegan PM; Wilder CL; Platt MO
    Mol Cell Biochem; 2012 Aug; 367(1-2):65-72. PubMed ID: 22562303
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The S2 subsites of cathepsins K and L and their contribution to collagen degradation.
    Lecaille F; Chowdhury S; Purisima E; Brömme D; Lalmanach G
    Protein Sci; 2007 Apr; 16(4):662-70. PubMed ID: 17384231
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design of cathepsin K inhibitors for osteoporosis.
    Deaton DN; Tavares FX
    Curr Top Med Chem; 2005; 5(16):1639-75. PubMed ID: 16375747
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biochemical properties and regulation of cathepsin K activity.
    Lecaille F; Brömme D; Lalmanach G
    Biochimie; 2008 Feb; 90(2):208-26. PubMed ID: 17935853
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-covalent cathepsin K inhibitors for the treatment of osteoporosis.
    Kim TS; Tasker AS
    Curr Top Med Chem; 2006; 6(4):355-60. PubMed ID: 16611147
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cathepsin K and the design of inhibitors of cathepsin K.
    Yamashita DS; Dodds RA
    Curr Pharm Des; 2000 Jan; 6(1):1-24. PubMed ID: 10637370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate.
    Li Z; Hou WS; Escalante-Torres CR; Gelb BD; Bromme D
    J Biol Chem; 2002 Aug; 277(32):28669-76. PubMed ID: 12039963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human cathepsin X: A cysteine protease with unique carboxypeptidase activity.
    Nägler DK; Zhang R; Tam W; Sulea T; Purisima EO; Ménard R
    Biochemistry; 1999 Sep; 38(39):12648-54. PubMed ID: 10504234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A cytochemical assay for osteoclast cathepsin K activity.
    Dodds RA
    Cell Biochem Funct; 2003 Sep; 21(3):231-4. PubMed ID: 12910475
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of activity-based probes for cathepsin X.
    Paulick MG; Bogyo M
    ACS Chem Biol; 2011 Jun; 6(6):563-72. PubMed ID: 21322635
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of cathepsin K by nitric oxide donors: evidence for the formation of mixed disulfides and a sulfenic acid.
    Percival MD; Ouellet M; Campagnolo C; Claveau D; Li C
    Biochemistry; 1999 Oct; 38(41):13574-83. PubMed ID: 10521264
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Localization patterns of cathepsins K and X and their predictive value in glioblastoma.
    Breznik B; Limback C; Porcnik A; Blejec A; Krajnc MK; Bosnjak R; Kos J; Van Noorden CJF; Lah TT
    Radiol Oncol; 2018 Oct; 52(4):433-442. PubMed ID: 30367810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.